China Top Nitroxoline Clinical Studies Suppliers?

China’s expanding research infrastructure has increased interest in Nitroxoline Clinical Studies. Nitroxoline is an established antibacterial compound with renewed attention in repurposing research. Its clinical development still requires careful evidence review, experienced investigators, and dependable laboratory support.

IQVIA Institute reported 22,825 products in the global biopharmaceutical pipeline in 2023. This figure shows intense competition for qualified clinical research capacity. However, it does not rank nitroxoline suppliers or confirm product quality. The WHO International Clinical Trials Registry Platform also demonstrates the importance of transparent trial registration across national databases. These sources provide useful context, not automatic supplier approval.

A reliable China-based supplier should demonstrate documented experience with protocol design, ethics submissions, patient recruitment, biological sample handling, and data management. NMPA-aligned quality systems matter. So do audit trails, validated analytical methods, and clear investigational product records. Ask for recent inspection outcomes when legally shareable. Request redacted study reports, not only marketing slides.

Details reveal operational strength. Can the team maintain a −80°C sample log? Can it explain deviation handling within one working day? Can it identify a qualified principal investigator for urinary tract or oncology research? These practical answers often matter more than a long service list.

Still, supplier comparisons remain imperfect. Public information may be incomplete, and “top” can mean different things. Cost, speed, therapeutic expertise, and compliance rarely peak together. This introduction therefore evaluates Chinese suppliers through verifiable capabilities, published evidence, and risk-aware due diligence. Experience is valuable. Evidence is essential.

Table of Contents [Hide]

1 Nitroxoline: Chemical Profile, Formula C9H6N2O3, and MW 190.16

2 China’s Nitroxoline Clinical Research Supplier Landscape and Market Scope

3 Supplier GMP, ISO 13485, and GLP Compliance for Nitroxoline Studies

4 Clinical-Grade Nitroxoline: Purity Targets, Batch Data, and COA Standards

5 Comparing Chinese Suppliers by CRO Capacity, Pharmacology, and Study Support

Nitroxoline: Chemical Profile, Formula C9H6N2O3, and MW 190.16

China Top Nitroxoline Clinical Studies Suppliers?

Nitroxoline has the molecular formula C9H6N2O3 and a molecular weight of 190.16 g/mol. It is a nitro-substituted hydroxyquinoline compound with a rigid aromatic structure. The hydroxyl and ring nitrogen can influence metal binding and analytical behavior. Its yellow crystalline appearance may support basic identity checks, but appearance alone proves little.

For clinical research sourcing in China, I would examine the chemical profile before comparing suppliers. A reliable dossier should include a current certificate of analysis, HPLC purity, impurity data, residual solvent results, and batch traceability. LC-MS, NMR, and elemental analysis can strengthen identity confirmation. Nitroxoline may show limited water solubility, so the tested solvent system must be recorded carefully. I have seen poor conclusions arise from incomplete sample preparation. That detail deserves more attention.

Tips: Request a representative sample and review its stability data. Check whether testing follows recognized pharmacopeial or validated laboratory methods. Confirm storage conditions, packaging integrity, and documentation for the intended research use. Do not treat a high purity number as complete evidence of quality. Supplier qualification should also consider manufacturing controls, change notification, and applicable Chinese and international requirements.

China’s Nitroxoline Clinical Research Supplier Landscape and Market Scope

China’s nitroxoline clinical research supplier landscape covers more than drug manufacturing. It includes clinical research organizations, analytical laboratories, trial supply providers, and medical data specialists. Each supports a different stage of development.

Experienced suppliers usually provide protocol support, site coordination, patient screening, sample logistics, and electronic data capture. Analytical laboratories may measure drug levels, metabolites, and safety markers under validated procedures. Temperature-controlled transport matters because blood and urine samples can lose quality during delays. Clear chain-of-custody records are essential.

Market scope is growing around research partnerships, especially for repurposing studies and hospital-based investigations. Qualified suppliers should understand Chinese clinical requirements, ethics review, informed consent, and quality management. They also need documented training and audit-ready records. Public information can be incomplete. That makes direct verification necessary.

No supplier is perfect. Some teams have strong laboratory systems but limited multicenter experience. Others coordinate hospitals well but provide weak data transparency. Buyers should compare inspection history, staff expertise, turnaround times, and corrective-action practices. Cost alone is a poor filter. A low quote may exclude sample storage, monitoring visits, or database cleaning. Careful due diligence remains necessary.

Supplier GMP, ISO 13485, and GLP Compliance for Nitroxoline Studies

China’s leading nitroxoline clinical study suppliers should offer more than competitive pricing. Reliable partners connect GMP manufacturing, ISO 13485 quality systems, and GLP laboratory controls. These standards support consistent materials, documented processes, and credible study data.

GMP oversight should cover raw material checks, batch records, storage temperatures, and deviation handling. ISO 13485 adds disciplined risk management for medical products and related services. GLP compliance matters for nonclinical testing, sample tracking, equipment calibration, and final reports. Experienced teams should review certificates, audit histories, quality agreements, and corrective action records. A polished certificate can still hide gaps. Site visits and document checks remain useful.

Tips: Ask for a supplier qualification package before signing. Check whether procedures match the actual study scope. Confirm chain-of-custody records for every sample. Review how the laboratory handles failed controls and unexpected results. Request realistic timelines, not optimistic promises. Small omissions can affect confidence later. Even strong suppliers may need closer monitoring when methods change, staff turnover rises, or multiple facilities share responsibilities. Clear communication with clinical, laboratory, and quality personnel helps prevent avoidable delays.

Clinical-Grade Nitroxoline: Purity Targets, Batch Data, and COA Standards

China Top Nitroxoline Clinical Studies Suppliers?

Clinical-grade nitroxoline begins with a clear specification, not a sales claim. Purity targets should define assay, related substances, residual solvents, water content, and elemental impurities. The exact limits should match the study protocol and applicable regulatory expectations. A strong supplier provides current batch data, not only a standard product sheet. That distinction matters.

Review the certificate of analysis line by line. It should identify the material, lot number, manufacturing date, retest date, test methods, and specification limits. Identity testing may include chromatographic comparison and spectroscopic confirmation. Assay results should show the method and reported value. Impurity data need named peaks or clear reporting thresholds. Missing details create avoidable uncertainty.

Inspect the original chromatograms when possible. A clean table is useful, but raw evidence is stronger. Check whether the tested batch matches the shipped batch. Also verify storage conditions, packaging, and chain-of-custody records. A qualified supplier should explain deviations without vague language. Clinical-grade is not a universal label. It requires documented control.

Some COAs look complete but lack method validation information. That weakness deserves attention. I would request representative batch records, laboratory accreditation details, and change-control procedures before approval. One more practical check: compare several lots for assay consistency and impurity patterns. Perfect uniformity is uncommon, so unexplained variation should not be ignored.

China Top Nitroxoline Clinical Studies Suppliers? - Clinical-Grade Nitroxoline: Purity Targets, Batch Data, and COA Standards

Data Dimension	Clinical-Grade Target or Requirement	Batch / COA Evidence	Applicable Standard or Technical Basis
Chemical identity	Nitroxoline; 5-nitroquinolin-8-ol	Name, structure, CAS number, molecular formula and molecular weight shown on the COA	CAS 4008-48-4; molecular formula C₉H₆N₂O₃; relative molecular mass approximately 190.16 g/mol
Appearance	Uniform yellow to orange-yellow powder; no visible foreign particles	Recorded visual inspection result, sample quantity and test date	Approved internal specification; visual description should be confirmed against the validated material specification
Assay / purity	Recommended procurement target: not less than 99.0% by a validated HPLC method, unless the study protocol defines another limit	Actual result, specification, analytical method, reference standard and chromatogram or electronic data reference	ICH Q6A concepts for specifications and ICH Q2(R2) principles for analytical procedure validation; the 99.0% value is a buyer-defined target, not a universal monograph limit
Identity confirmation	Positive identification by at least two orthogonal techniques	FTIR spectrum with reference comparison plus HPLC retention time; LC-MS may be used as an additional confirmation	Validated or qualified identity procedures consistent with ICH Q2(R2)
Related substances	Individual and total organic impurities controlled using predefined, scientifically justified limits	Impurity profile, reporting threshold, identification threshold, quantitation method and chromatographic data	ICH Q3A(R2) framework for organic impurities; limits must be justified for the intended development stage and dose
Water content	Suggested release target: not more than 1.0% by Karl Fischer titration, subject to stability data	Karl Fischer result, method version, sample condition and test date	ICH Q6A-style specification setting; the numerical limit should be supported by material and stability studies
Residual solvents	Each detected solvent controlled according to its ICH classification and permitted concentration	GC results reported by solvent, concentration, limit and reporting unit; “not detected” must include the detection limit	ICH Q3C(R8) residual-solvent classification and concentration limits
Elemental impurities	Risk-based evaluation for elements potentially introduced by raw materials, catalysts, equipment or packaging	ICP-MS or ICP-OES results, tested elements, limits, units and sample preparation details	ICH Q3D(R2) elemental-impurity risk-management principles
Particle characteristics	Particle-size distribution defined only when relevant to dissolution, formulation, inhalation, suspension or dosing performance	D10, D50 and D90 values, analytical technique, dispersion medium and sampling procedure	Application-specific material specification; laser diffraction or microscopy may be used when scientifically justified
Microbiological quality	Microbial limits established according to the dosage form and study use; sterile API is not implied by a standard non-sterile powder COA	Total aerobic microbial count, total yeast and mold count, specified organisms, or sterility result where applicable	Pharmacopoeial microbiological methods and the approved clinical formulation specification
Batch traceability	One unique batch number linked to raw-material, manufacturing and testing records	Batch number, batch size, manufacturing date, packaging date, test date and certificate issue date	Good documentation practice and pharmaceutical quality-system expectations
Retest / expiry information	Retest date supported by real-time or accelerated stability data; an expiry date should not be assigned without appropriate stability justification	Storage condition, container-closure system, retest date, stability interval and approved storage statement	ICH Q1A(R2) stability principles and documented change-control procedures
Packaging and storage	Protect from light and moisture in a tightly closed, chemically compatible container; exact conditions must be supported by stability data	Container material, seal status, net quantity, storage temperature and humidity statement	Stability-indicating packaging and storage assessment
Analytical laboratory qualification	Testing performed by a qualified laboratory with controlled methods, calibrated instruments and traceable reference materials	Laboratory authorization, analyst approval, instrument identification, calibration status and method version	ISO/IEC 17025 principles for laboratory competence; GMP expectations where applicable
Clinical-study suitability statement	COA compliance alone does not establish suitability for human administration; clinical use requires qualified manufacturing, formulation, toxicology, stability and regulatory review	Signed quality-release statement, deviation status, change history and supporting development documentation	Applicable clinical-trial, GMP and regulatory requirements in the study jurisdiction

Note: Numerical acceptance values shown as “recommended,” “suggested,” or “buyer-defined” are procurement targets rather than universal pharmacopeial requirements. Final specifications should be approved for the intended formulation, route of administration, development phase and jurisdiction.

Comparing Chinese Suppliers by CRO Capacity, Pharmacology, and Study Support

China Top Nitroxoline Clinical Studies Suppliers?

Selecting a Chinese supplier for nitroxoline studies requires more than comparing prices. CRO capacity should match the protocol’s real workload. Ask whether the team can manage ethics submissions, site coordination, patient screening, and sample logistics. A capable group should also show validated data systems and documented quality controls. Look for practical evidence. For example, can it explain how urine samples move from a hospital refrigerator to bioanalysis?

Pharmacology expertise deserves equal attention. Nitroxoline studies may require antibacterial assessment, pharmacokinetic analysis, tissue distribution, or exposure-response interpretation. Suppliers should describe their LC-MS/MS methods, assay sensitivity, reference standards, and stability testing. Their scientists must connect laboratory findings with clinical endpoints. Clear answers matter. Vague claims do not.

Study support often separates a functional partner from a convenient vendor. Strong suppliers can help refine inclusion criteria, sampling schedules, investigator training, and safety reporting workflows. They should provide named responsibilities, milestone dates, and realistic contingency plans. Smaller teams may offer closer scientific communication, while larger CROs may provide broader site coverage. Neither model is automatically better. A spreadsheet alone can mislead. During due diligence, request anonymized examples of deviation handling, monitoring reports, and database-lock preparation. One weakness remains easy to overlook: some teams present excellent pharmacology but limited experience coordinating multicenter studies. That gap should be tested before contracting.

China Nitroxoline Clinical Study Supplier Evaluation Framework

This chart uses an evidence-oriented screening framework rather than company names or unverified vendor rankings. The dimensions reflect the core support areas normally required for nitroxoline clinical development in China: clinical operations, pharmacology and PK/PD, bioanalysis, and regulatory documentation. Scores represent the relative evaluation weight assigned to each capability and should be confirmed against individual supplier evidence, such as relevant protocols, validated analytical methods, investigator networks, and NMPA submission experience.